Loading stock data…
LFMD
$4.97+0.15 (+3.22%)
Market OpenUpdated 2:58 PM EDT
LifeMD, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LifeMD, Inc. in the Healthcare sector is trading at $4.97. Wall Street consensus targets $9.88 (8 analysts), implying a +98.5% move over the next 12 months. The stock is currently near its 52-week low of $2.56, remaining 10.8% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +98.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $50.16M↑ | $7.08M↓ | $60.17M↓ | $62.22M↑ | $50.89M |
| Gross Profit | $44.24M↑ | $2.85M↓ | $52.76M↓ | $54.79M↑ | $42.75M |
| Operating Income | -$8.93M↓ | -$6.22M↓ | -$1.97M↓ | -$906,772↑ | -$1.18M |
| Net Income | -$8.87M↓ | $19.96M↑ | -$3.81M↓ | -$2.07M↓ | -$183,778 |
Peer Comparison
JNJUNHPFE
Fundamentals
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platf...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
34.65%
Volume
Today's trading volume
623,223
Recent News
How The Story Is Evolving For LifeMD (LFMD) With An Unchanged Fair Value View
LifeMD’s latest analyst update comes with no change to the current price target, keeping expectations steady for now. Even without fresh commentary, the unchanged target still sends a signal about how analysts are holding their view. Looking ahead, you will see how to track these kinds of shifts so you can stay in step with the evolving LifeMD story. Stay updated as the Fair Value for LifeMD shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover...
May 2026's Promising Penny Stocks To Watch
The United States market has shown a positive trend, with a 1.3% increase over the last week and a 28% rise over the past year, alongside an anticipated annual earnings growth of 17%. Investing in penny stocks — once considered more mainstream but now seen as niche — can still offer access to potential growth opportunities, particularly in smaller or newer companies. We've identified three penny stocks that demonstrate strong financial health and long-term potential, offering investors a...
GLP-1 Users Turn to Telehealth to Access Weight Loss Drugs
Justin Schrieber, CEO of telehealth company LifeMD, said that the main reason that Americans end up at virtual health care providers is to access GLP-1 weight loss medication, as well as other prescription medication. Schreiber said that there is still an untapped market for GLP-1 access and the next frontier of virtual access is for hormone replacement care.
LifeMD, Inc. Q1 2026 Earnings Call Summary
Moby summary of LifeMD, Inc.'s Q1 2026 earnings call
LifeMD Q1 Earnings Call Highlights
LifeMD (NASDAQ:LFMD) reported first-quarter 2026 results that management said marked a strong start to the year, highlighted by revenue that topped guidance and record subscriber growth as the company continued shifting its weight management business toward branded GLP-1 therapies and expanded insur